长江商报消息 ●长江商报记者 沈右荣 复星医药（600196.SH）卖资产加码创新药布局。 9月26日晚，复星医药发布公告，公司拟出资5460万元参与设立专项基金，基金成立后，公司拟将上海克隆100% 股权作价12.56亿元转让给专项基金，而上海克隆的主要资产为物业。 复星医药称，上述动作是为了进一步聚焦核心业务并提升资产运营效率，转让所得款项将用于创新药业务的持续 投入。 长江商报记者注意到，复星医药频频处置非核心业务资产。2025年以来，公司已签约处置项目总额超20亿元。 同时，公司持续加码创新药。2025年上半年，在治疗药物方面，复星医药自主研发及许可引进的4个创新药品共5 项适应症于境内外获批、4个创新药品申报上市。 过去三年，复星医药的研发投入合计达173.76亿元。2025年上半年，公司研发投入为25.84亿元。三年半时间，公 司研发投入合计199.6亿元。 而创新药驱动了复星医药的业绩增长。2025年上半年，公司实现归母净利润17.02亿元，同比增长38.96%。 复星医药再度处置资产，加码创新药业务布局。 根据公告，复星医药控股子公司复星医药产业拟筹划转让上海克隆100%股权（其主要资产为位于 ...

Core Viewpoint - Fosun Pharma has announced its Q1 2025 financial results and a restructuring of its board, indicating a strategic shift towards innovation and international collaboration [1][2]. Group 1: Financial Performance - Fosun Pharma reported a revenue of RMB 9.42 billion and a net profit attributable to shareholders of RMB 765 million for Q1 2025 [1]. - The operating cash flow for the quarter was RMB 1.056 billion, reflecting the company's ongoing operational efficiency [1]. Group 2: Leadership Changes - Wu Yifang has transitioned from Executive Director and Chairman to Non-Executive Director, while Wang Kexin continues as Executive Director and takes on the role of Co-Chairman [1]. - Chen Yuqing has been appointed as Chairman and Executive Director, with responsibilities for strategic development and organizational growth [1]. Group 3: Innovation and Product Development - The company has made significant progress in its innovation transformation, with the approval of its self-developed drug, Hetronifly, in the EU and the introduction of the first phosphate absorption inhibitor in China [1]. - Multiple innovative pipelines are entering critical clinical and approval stages, showcasing the company's commitment to R&D [1]. Group 4: Global Collaboration - Fosun Pharma has strengthened its international strategy by granting exclusive commercialization rights for its biosimilar HLX15 to Dr. Reddy's in the US and 42 European countries [2]. - A strategic partnership with Fakeeh Care Group in Saudi Arabia aims to advance various leading therapies, contributing to the region's healthcare landscape and supporting Saudi Arabia's Vision 2030 [2]. Group 5: Share Buyback Program - Fosun Pharma has initiated a new round of share buybacks, purchasing 1,613,300 A-shares for approximately RMB 39.99 million and 1,655,500 H-shares for about HKD 22.91 million in Q1 2025 [3].